SCHEMBL344626

SCHEMBL344626

COCOc1cc(-c2c(F)c(C#N)c3ccccn23)ccc1C(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.39
KMT2A Q03164 7/20 0.39
MAPT P10636 6/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 9/20 0.39
KDM4E B2RXH2 6/20 0.39
MAPK1 P28482 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 3/20 0.38
LMNA P02545 2/20 0.38
PPARG P37231 2/20 0.38
NCOR2 Q9Y618 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
PABPC1 P11940 2/20 0.37
CASP3 P42574 1/20 0.37
HTT P42858 1/20 0.37
NCOA1 Q15788 1/20 0.37
SENP6 Q9GZR1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL343566 0.86 MAPT (0.41) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL345253 0.80 ALDH1A1 (0.40) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL344160 0.79 ALDH1A1 (0.41) MEN1KMT2AMAPTUSP2ALDH1A1
SCHEMBL345289 0.74 XDH (0.46) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL342350 0.70 ALDH1A1 (0.46) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL15158182 0.69 XDH (0.36) KDM4ECHEK1AURKADAPK3JAK2
SCHEMBL15158058 0.69 MAPT (0.38) MAPTKDM4EHTTGAACHEK1
SCHEMBL187037 0.67 FFAR4 (0.59) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL7920655 0.65 MRGPRX4 (0.45) MAPTKDM4ETDP1AURKAABL1
SCHEMBL10280565 0.65 MCL1 (0.54) ALDH1A1LMNAHPGDEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748452-B2 Indolizine derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-06-10 US disclosed
EP-2415771-B1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL (JP) 2013-07-31 EP disclosed
EP-2415771-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Kissei Pharmaceutical Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES XDH, INMT, PON1 MEN1 2393/4885KMT2A 2454/4885MAPT 3604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.